In the context of IPF therapy, a phase II clinical trial of Pamrevlumab (FG-3019), a therapeutic antibody against CTGF, has been completed, and Pamrevlumab is expected to be developed as a next-generation pulmonary fibrosis treatment due to its significant effects on lung fibrosis and low toxicity32. The gene discussed is CCN2; the disease is idiopathic pulmonary fibrosis.